Background: Leishmaniasis is a stigmatic and mutilating disease due to pathogenic species of the genus Leishmania which, depending on the species and the individual's immune status, may vary clinically from a cutaneous, mucosal, and visceral form, and for which there is no suitable treatment without significant side effects. Methods: The method of [3-(3,4 -dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide] was used to study the antiparasitic effects of ethanolic (100mg/mL) and aqueous (100mg/mL) extracts of Psidium guajava on axenic amastigotes cultures (8.1 x103 parasite/mL) and promastigotes (12 x 104 parasite/mL) obtained from a patient with cutaneous leishmaniasis, and the percentage of parasite death was evaluated in comparison with Glucantime (300mg/mL) and untreated parasite cultures. Results: Regarding parasite death in promastigotes, the ethanolic and aqueous extracts had a percentage of 22.58% and -45.16%, respectively, with no significant difference between treatments (N=3) (p= 0.058). In contrast, the ethanolic and aqueous extracts had an antiparasitic percentage of 91.67% and -70.83%, respectively, with a significant difference between treatments (N=3) (p<0.05). Conclusions:Our study showed high and significant effectiveness in parasite death (91.67%) of Leishmania axenic amastigotes of the ethanolic extract (100mg/mL) of Psidium guajava, being this result promising and the basis for in vivo studies, using the ethanolic extraction of P. guajava.

Background: Leishmaniasis is a stigmatic and mutilating disease due to pathogenic species of the genus Leishmania which, depending on the species and the individual's immune status, may vary clinically from a cutaneous, mucosal, and visceral form, and for which there is no suitable treatment without significant side effects. Objectives: To measure the effect of ethanolic and aqueous extracts of Psidium guajava against axenic promastigotes and amastigotes of Leishmania spp. Methods: The method of [3-(3,4 -dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was used to study the antiparasitic effects of ethanolic (100mg/mL) and aqueous (100mg/mL) extracts of Psidium guajava on axenic amastigotes cultures (8.1 x10 3 parasite/mL) and promastigotes (12 x 10 4 parasite/mL) obtained from a patient with cutaneous leishmaniasis, and the percentage of parasite death was evaluated in comparison with Glucantime (300mg/mL) and untreated parasite cultures. Results: Regarding parasite death in promastigotes, the ethanolic and aqueous extracts had a percentage of 22.58% and -45.16%, respectively, with no significant difference between treatments (N=3) (p= 0.058). In contrast, the ethanolic and aqueous extracts had an antiparasitic percentage of 91.67% and -70.83%, respectively, with a significant difference between treatments (N=3) (p<0.05). Conclusions: Our study showed high and significant effectiveness in parasite death (91.67%) of Leishmania axenic amastigotes of the ethanolic extract (100mg/mL) of Psidium guajava, being this result promising and the basis for in vivo studies, using the ethanolic extraction of P. guajava.

Background: Leishmaniasis is a disease caused by the Leishmania parasite, which is difficult to diagnose, causes disfigurement and is difficult to treat. Objectives: To determine the effect of Butionin-Sulfaximine (BSO) and Fluphenazine on trypomastigotes and axenic amastigotes of Leishmania peruviana and Leishmania braziliensis. Methods: A study was performed with Butionin-Sulfaximine (BSO), Fluphenazine, and Glucantime (positive control,) utilizing respective concentrations of 41.7 mg/ml, 4.17 mg/ml, and 50 mg/ml for twenty-four hours on axenic amastigotes. Results: A significant difference (*P < 0.05) was found between the negative control group, Fluphenazine, and BSO within both the axenic amastigotes of L. peruviana (5.5 X 10 5 / ml for the negative control, 0.15 X 10 5 / ml for Fluphenazine, and 0.7 X 10 5 / ml for BSO) and L. braziliensis (6.9 X 10 5 /ml for the negative control, 0.18 X 10 5 /ml for Fluphenazine, and 0.22 X 10 5 /ml for BSO). Another significant difference (*P < 0.05) was found in the promastigotes of L. peruviana (5.9 X 10 5 / ml for the negative control, 0.66 X 10 5 / ml for Fluphenazine, and 3.1 X 10 5 / ml for BSO) and L. braziliensis (8.7 X 10 5 /ml for the negative control and 5.68 X 10 5 /ml for Fluphenazine). Conclusions: From this, we conclude Fluphenazine and BSO present promising antiparasitic effects against axenic amastigotes of L. peruviana and L. braziliensis in both pharmacological tests of the in vivo model and their potential future use.

No abstract